Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4387 | azoximer bromide Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The primary aim of this study is to determine whether implementation of a postpartum patient navigation program improves health outcomes among low-income women. Patient navigation is a barrier focused, long-term patient-centered intervention that offers support for a defined set of health services. The intervention under investigation is a comprehensive postpartum patient navigator program. Women who are randomized to receive patient navigation will be compared to women who are randomized to receive usual care. Navigators will support women through one year postpartum. The NNM2 program will be grounded in understanding and addressing social determinants of health in order to promote self-efficacy, enhance access, and sustain long-term engagement. Participants will undergo surveys, interviews, and medical record review at 4-12 weeks and 11-13 months postpartum. The investigators will additionally conduct focus groups and surveys with clinical providers.
Description: Number of women who achieve a composite measure of health status that includes retention in care, receipt of recommended counseling (anticipatory guidance), receipt of desired contraception, postpartum depression screening and care, breastfeeding initiation and maintenance, and receipt of preventive care. (Outcome is modified to include receipt telemedicine for health care for women who require postpartum care during the pandemic)
Measure: Postpartum health at 4-12 weeks after delivery Time: 4-12 weeks postpartumDescription: Among women with gestational diabetes mellitus (GDM), number of women with completion of a 2-hour oral glucose tolerance test by 12 weeks postpartum
Measure: Postpartum diabetes screening Time: 4-12 weeks and 1 year postpartumDescription: Among women with ASCVD-associated adverse pregnancy outcomes, number of women who undergo indicated clinical assessments for blood pressure, lipids, weight, nutrition, activity
Measure: Postpartum atherosclerotic cardiovascular disease screening Time: 4-12 weeks and 1 year postpartumDescription: Difference between weight at delivery and 1) weight at early postpartum (4-12 weeks) and 2) weight at 1 year postpartum
Measure: Gestational weight retention Time: 4-12 weeks and 1 year postpartumDescription: Total duration of exclusive or partial breastfeeding among women who desired breastfeeding
Measure: Breastfeeding Time: 4-12 weeks and 1 year postpartumDescription: Number of women with appointment made and kept for primary care by 1 year postpartum
Measure: Postpartum transition to primary care Time: 1 year postpartumDescription: Differences between self-efficacy, activation, and engagement between women who are randomized to navigation versus usual care, using the Department of Health and Human Services (DHHS) Patient-Reported Outcomes Measurement Information System.
Measure: Patient-reported outcomes - self-efficacy, activation, and engagement Time: 4-12 weeks and 1 year postpartumDescription: Qualitative perspectives on experiences with the navigation program, based on interviews with women who received navigation
Measure: Experiences with navigation Time: 3-6 months postpartum and 1 year postpartumDescription: Qualitative perspective of participants' experiences during the COVID-19 pandemic, utilizing a semi-structured interview guide developed by the research team, as it relates to their receipt of health care, experiences as a pregnant person and new parent, and the role of patient navigation in this time period
Measure: Pregnancy/postpartum experiences during the pandemic Time: At any point during the COVID-19 pandemic, up to 3 months after the end of the pandemicDescription: Qualitative feedback on how NNM2 can meet the needs of the clinicians and optimize the transition to primary care, as assessed by feedback from obstetrician and primary care provider focus groups
Measure: Evaluate clinician perspectives on patient navigation Time: Through completion of study, an average of 3 yearsDescription: Number of clinicians who believed NNM2 met their needs and improved patient care, as determined by surveys feedback
Measure: Evaluate clinician experiences with NNM2 Time: Through completion of study, an average of 5 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports